NanoViricides

NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoViricides, Inc. is a clinical stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon. The Phase 1 clinical trial, protocol number KM-NVCoV2-001, which received approval from the regulatory agency in India for healthy as well as COVID-19 participants, was closed and completed in April by the Drug Sponsor and our licensee, Karveer Meditech, Pvt.

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

NanoViricides (NYSE-A:NNVC) said it is making good progress in its antiviral drug development program, with strong safety data for its lead candidate NV-CoV-2 and enhanced liquidity measures positioning the company for future clinical trials and market expansion. Financially, NanoViricides (NYSE-A:NNVC) reported a cash and cash equivalent current assets balance of approximately $5.31 million as of December 31, 2023, with additional agreements providing approximately $2.5 million available cash, totaling around $7.8 million cash available to the company.

NanoViricides boosts liquidity measures and manufacturing capacity to support clinical trials

SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending December 31, 2023 with the Securities and Exchange Commission (SEC) on Wednesday, February 14, 2024. The report can be accessed at the SEC website at https://www.sec.gov/Archives/edgar/data/1379006/000141057824000048/nnvc-20231231x10q.htm.

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

NanoViricides (NYSE-A:NNVC) has a platform that shows a versatile and effective approach to antiviral therapy, with potential applications that target a broad spectrum of viral diseases. The clinical stage company, pioneering nanomedicine for antiviral therapy, is making significant strides in its fight against viral infections.

Pioneering nanomedicine: NanoViricides making big strides fighting viral infections

NanoViricides (NYSE-A:NNVC) told investors it believes that the strong safety and tolerability of its NV-CoV-2 oral drug products containing the active ingredient NV-387 shows that they have implications beyond COVID. NV-387 is an ultra-broad-spectrum antiviral nanomedicine that was designed by copying a common host-side chemical signature used by viruses to infect and cause disease in humans and animals, the company said.

NanoViricides highlights lead asset NV-387's potential to revolutionize the treatment of antiviral infections

SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, explains that the demonstration of strong safety and tolerability of NV-CoV-2 oral drug products has implications beyond COVID, setting the Company up for long term success and growth. NV-CoV-2 drugs contain the active pharmaceutical ingredient NV-387.

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

NanoViricides (NYSE-A:NNVC) has earned a ‘Buy' rating and a $6.50 price target from EFHutton analysts after the company released positive safety results from its Phase 1a/1b clinical study involving its lead asset NV-387. Shares of NanoViricides (NYSE-A:NNVC) traded hands at about US$1.12 on Tuesday afternoon.

NanoViricides' potential to address dozens of diseases highlighted by analysts following trial success

Drug developer NanoViricides (NYSE-A:NNVC) Inc said it has successfully completed its phase Ia/Ib clinical trial of NV-CoV-2, its lead asset. Involving healthy subjects, the study was concluded without any adverse events, a key element to early human studies.

NanoViricides successfully concludes first-in-human study

SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the healthy subjects part of the Phase 1a/1b Clinical Trial of NV-CoV-2 was completed successfully. No adverse events were reported in any of the multiple ascending dose cohorts, confirming the excellent safety of NV-387, the active ingredient in NV-CoV-2.

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it is presenting at Biotech Showcase™ 2024. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco Day & Date Tuesday, January 9, 2024 Time, Track & Room 3:30pm PT, Yosemite C (Ballroom Level) Location Hilton San Fransisco - Union Square This year, registered attendees can view NanoViricides' presentation live, and also access a recorded version after the event.

NanoViricides to Present at the Biotech Showcase in San Fransisco

Spectrum Pharma

NanoViricides (NYSE-A:NNVC) has successfully wrapped up the first phase of a human clinical trial for its broad-spectrum antiviral drug, NV-CoV-2. The company said that the drug was well-tolerated, with no adverse events reported in any of the three dose levels from the two formulations used in the study, namely NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies.

NanoViricides completes Phase 1a/1b human clinical trial for its broad-spectrum antiviral drug

SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Single-Ascending Dose part of the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's broad-spectrum antiviral drug, was completed successfully. Recruitment for the Multiple-Ascending Dose part was also completed.

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

NanoViricides (NYSE-A:NNVC) said it exited the third quarter with enough cash on hand to progress clinical trials involving its lead drug candidate NV-CoV-2 for SARS-CoV-2 which causes COVID. NV-CoV-2 is currently being evaluated in Phase 1a/1b human trials in India by NanoViricides (NYSE-A:NNVC)' collaborator Karveer Meditech.

NanoViricides continues to progress antiviral drug candidate NV-CoV-2 in 3Q

SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2023 with the Securities and Exchange Commission (SEC) on Tuesday, November 14, 2023. The report can be accessed at the SEC website at https://www.sec.gov/ix?doc=/Archives/edgar/data/0001379006/000141057823002484/nnvc-20230930x10q.htm.

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

NanoViricides (NYSE-A:NNVC) has announced that its broad-spectrum antiviral drug candidate NV-387 in development for MPox and Smallpox was shown to be “highly effective” for these indications in an animal model. During the trial, animals treated with NV-387 matched the 14-day survival rate of animals on oral Tecovirimat, an approved smallpox therapeutic.

NanoViricides drug candidate found to be ‘highly effective' for MPox and Smallpox in animal trial

SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reports that its broad-spectrum antiviral drug candidate, NV-387 was highly effective in an animal model that is used in drug development for MPox and Smallpox virus infections in humans. NV-387 is currently in Phase 1a/1b human clinical trials for COVID-19 indication in India, under sponsorship by our licensee and collaborator, Karveer Meditech, Pvt.

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development

NanoViricides (NYSE-A:NNVC) said it has sufficient funds to complete its ongoing Phase 1a/1b clinical trial of its lead drug candidate NV-CoV-2 based on its “nanoviricle” active pharmaceutical ingredient NV-387 for coronavirus. The company said NV-387 was “highly active” when tested against coronavirus, including SARS-CoV-2, in pre-clinical studies, and it is expanding its pre-clinical studies to evaluate the antiviral activity of NV-387 against other viruses.

NanoViricides updates investors on Phase 1a/1b trial of antiviral drug candidate for coronavirus

SHELTON, CT / ACCESSWIRE / October 16, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023 with the Securities and Exchange Commission (SEC) on Friday, October 13, 2023. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057823002146/nnvc-20230630x10k.htm).

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV

SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Partnership Opportunities in Drug Delivery (PODD) Conference in Boston, MA, on October 16, 2023 at 6:07pm ET in Track 2B. Dr. Diwan will present a talk entitled "Revolutionizing Antiviral Treatments - Orally Available Nanomedicines that Can Also Deliver Difficult APIs and Improve Their PK.

NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET

NanoViricides (NYSE-A:NNVC) has reported that the Phase 1a/1b human clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing successfully. According to the company's Indian collaborator and drug sponsor, Karveer Meditech, about 26 out of the target of 36 healthy volunteers in the various cohorts in the Phase 1a Single-Ascending-Dose (SAD) have already completed the study.

NanoViricides reports progress in Phase 1a/1b human clinical trial of NV-CoV-2 broad-spectrum antiviral drug

SHELTON, CT / ACCESSWIRE / August 21, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's broad-spectrum antiviral drug, is progressing successfully. Healthy Volunteers Recruitment for Phase 1a and Phase 1b is Progressing Satisfactorily: The Company reports that its Indian collaborator and drug sponsor, Karveer Meditech Pvt.

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides

As a war often accelerates technological innovation, the recent coronavirus pandemic in 2020 provided a big spur to advancements in biotechnology, with the rapid development of vaccines to contain the outbreak. One company that felt that boost is Connecticut-based firm, NanoViricides Inc (NYSE-A:NNVC), which for 20 years prior to the pandemic had been quietly working on creating special-purpose nanomaterials for antiviral therapy.

NanoViricides creating special purpose nanomaterials for antiviral therapy

NanoViricides Inc (NYSE-A:NNVC) has announced the promising efficacy of its antiviral drug candidate NV-387 in combating Respiratory Syncytial Virus (RSV) infection in an animal model. NV-387, the active ingredient of NV-CoV-2, the company's COVID treatment, has already entered Phase 1a/1b human clinical trials.

NanoViricides reveals promising efficacy of its antiviral drug candidate in combating RSV

SHELTON, CT / ACCESSWIRE / July 11, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV (Respiratory Syncytial Virus). NV-387 Can Advance Directly into Phase II Human Clinical Trials for RSV Treatment: NV-387 is the active ingredient of NV-CoV-2, the Company's drug for the treatment of COVID and possibly long COVID.

Company's Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides

NanoViricides Inc (NYSE-A:NNVC) has announced that the clinical trial of its broad-spectrum antiviral drug, NV-CoV-2, is progressing satisfactorily. The drug is being developed as a potential treatment for coronavirus infections, including COVID-19 and long COVID.

News for NanoViricides Stock (NNVC)